Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD

  title={Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD},
  author={Dana V. Rizk and A. B. Chapman},
  journal={Pediatric Nephrology},
Polycystic kidney disease (PKD) is the most common inherited renal disorder. Patients with PKD remain clinically asymptomatic for decades, while significant anatomic and physiologic systemic changes take place. Sequencing of the responsible genes and identification of their protein products have significantly expanded our understanding of the pathophysiology of PKD. The molecular basis for cystogenesis is being unraveled, leading to new targets for therapy and giving hope to millions of people… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 12 extracted citations

Antenatally Diagnosed ADPKD

Kidney international reports • 2018
View 8 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 67 references

Polycystic kidney disease.

The New England journal of medicine • 2004
View 4 Excerpts
Highly Influenced

Sonographic pattern of recessive polycystic kidney disease in young adults. Differences from the dominant form.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2000
View 8 Excerpts
Highly Influenced

Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.

Proceedings of the National Academy of Sciences of the United States of America • 2007
View 1 Excerpt

A phase IIB pilot study of the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA), in patients with ADPKD

AB Chapman, VE Torres, +3 authors FS Czerwiec
ASN 38th Annual Renal Week Meeting • 2006
View 1 Excerpt

Similar Papers

Loading similar papers…